-
1.发明授权公开(公告)号：US08563520B2
公开(公告)日：2013-10-22
申请号：US12154396
申请日：2008-05-22
申请人： H. Uri Saragovi
发明人： H. Uri Saragovi
IPC分类号： A61K39/395 , A61K47/06
CPC分类号： C07K16/18 , A61K2039/505 , C07K14/47 , C07K16/30 , C07K2317/76 , G01N33/5308 , G01N2800/168
摘要： The present invention relates to methods to treat glaucoma and glaucoma-related conditions through the regulation of changes in gene expression that are mediated by high intraocular pressure or α2 macroglobulin administration. Glaucoma, retinal ganglion cell (RGC) death and chronic ocular hypertension are treated using pharmaceutical compositions which comprise substances that inhibit the expression or activity of intraocular pressure-regulated early genes (IPREGs) or their gene products that are up-regulated by high intraocular pressure or α2 macroglobulin administration and/or which increase the expression or activity of IPREGs or their gene products that are down-regulated by high intraocular pressure or α2 macroglobulin administration. The invention also relates to methods of identifying an IPREG and methods to test for chronic ocular degeneration and the onset of RGC stress in an individual by measuring the expression level of IPREG proteins.
摘要翻译： 本发明涉及通过调节由高眼内压或α2巨球蛋白给药介导的基因表达变化来治疗青光眼和青光眼相关病症的方法。 使用药物组合物治疗青光眼，视网膜神经节细胞（RGC）死亡和慢性高眼压症，其包括抑制眼内压调节的早期基因（IPREG）或其高眼内压上调的基因产物的表达或活性的物质 或α2巨球蛋白施用和/或增加由高眼内压或α2巨球蛋白施用而下调的IPREG或其基因产物的表达或活性。 本发明还涉及通过测量IPREG蛋白的表达水平来鉴定IPREG的方法和测试个体中慢性眼变性和RGC应激发作的方法。
-
公开(公告)号：US20080305103A1
公开(公告)日：2008-12-11
申请号：US12154396
申请日：2008-05-22
申请人： H. Uri Saragovi
发明人： H. Uri Saragovi
CPC分类号： C07K16/18 , A61K2039/505 , C07K14/47 , C07K16/30 , C07K2317/76 , G01N33/5308 , G01N2800/168
摘要： The present invention relates to methods to treat glaucoma and glaucoma-related conditions through the regulation of changes in gene expression that are mediated by high intraocular pressure or α2 macgroglobulin administration. Glaucoma, retinal ganglion cell (RGC) death and chronic ocular hypertension are treated using pharmaceutical compositions which comprise substances that inhibit the expression or activity of intraocular pressure-regulated early genes (IPREGs) or their gene products that are up-regulated by high intraocular pressure or α2 macgroglobulin administration and/or which increase the expression or activity of IPREGs or their gene products that are down-regulated by high intraocular pressure or α2 macgroglobulin administration. The invention also relates to methods of identifying an IPREG and methods to test for chronic ocular degeneration and the onset of RGC stress in an individual by measuring the expression level of IPREG proteins.
摘要翻译： 本发明涉及通过调节由高眼内压或α2巨球蛋白给药介导的基因表达变化来治疗青光眼和青光眼相关病症的方法。 使用药物组合物治疗青光眼，视网膜神经节细胞（RGC）死亡和慢性高眼压症，其包括抑制眼内压调节的早期基因（IPREG）或其高眼内压上调的基因产物的表达或活性的物质 或α2巨球蛋白给药和/或增加由高眼内压或α2巨溴蛋白给药下调的IPREG或其基因产物的表达或活性。 本发明还涉及通过测量IPREG蛋白的表达水平来鉴定IPREG的方法和测试个体中慢性眼变性和RGC应激发作的方法。
-
公开(公告)号：US07423114B2
公开(公告)日：2008-09-09
申请号：US10528542
申请日：2005-11-28
申请人： Martin Gagnon , H. Uri Saragovi
发明人： Martin Gagnon , H. Uri Saragovi
CPC分类号： A61K38/1709 , C07K14/78 , G01N2405/10 , G01N2500/02
摘要： The invention provides ligands of ganglioside GD2, including peptide ligands such as GGITNYNSALM; YCGGITNYNSACY; YCITNYNSCY; YCGGITNYNCY; YCTNYGVHCY; YCTNYGVCY; GGIANYNTS; YCGGIANYNCY; YCGGIANYNTSCY; and, YCIANYNTCY. GD2 ligands of the invention may for example be used to treat or diagnose diseases such as cancers in which cells express GD2, including neuroblastomas.
摘要翻译： 本发明提供神经节苷脂GD2的配体，包括肽配体如GGITNYNSALM; YCGGITNYNSACY; YCITNYNSCY; YCGGITNYNCY; YCTNYGVHCY; YCTNYGVCY; GGIANYNTS; YCGGIANYNCY; YCGGIANYNTSCY; 和YCIANYNTCY。 本发明的GD2配体可以例如用于治疗或诊断疾病，例如细胞表达GD2的癌症，包括神经母细胞瘤。
-
公开(公告)号：US08648169B2
公开(公告)日：2014-02-11
申请号：US12312975
申请日：2007-12-05
申请人： H. Uri Saragovi
发明人： H. Uri Saragovi
IPC分类号： A61K38/00
CPC分类号： A61K31/138 , A61K38/12 , A61K45/06 , A61K2300/00
摘要： The present invention relates to methods of treating or preventing retinal ganglion cell (RGC) death and/or glaucoma using modulators of neurotrophic receptors that comprise β-turn peptidomimetic cyclic compounds or derivatives thereof. The neurotrophic receptor modulators can be used alone, in combination and/or in conjunction with one or more other compounds, molecules or drugs that treat or prevent ocular hypertension, RGC death and/or glaucoma.
摘要翻译： 本发明涉及使用包含β-转角肽模拟环状化合物或其衍生物的神经营养受体调节剂治疗或预防视网膜神经节细胞（RGC）死亡和/或青光眼的方法。 神经营养受体调节剂可以单独使用，和/或与一种或多种其它化合物，治疗或预防眼高血压，RGC死亡和/或青光眼的分子或药物结合使用。
-
公开(公告)号：US20100048461A1
公开(公告)日：2010-02-25
申请号：US12312975
申请日：2007-12-05
申请人： H. Uri Saragovi
发明人： H. Uri Saragovi
IPC分类号： A61K38/12
CPC分类号： A61K31/138 , A61K38/12 , A61K45/06 , A61K2300/00
摘要： The present invention relates to methods of treating or preventing retinal ganglion cell (RGC) death and/or glaucoma using modulators of neurotrophic receptors that comprise β-turn peptidomimetic cyclic compounds or derivatives thereof. The neurotrophic receptor modulators can be used alone, in combination and/or in conjunction with one or more other compounds, molecules or drugs that treat or prevent ocular hypertension, RGC death and/or glaucoma.
摘要翻译： 本发明涉及使用包含β-培养模拟环状化合物或其衍生物的神经营养受体调节剂治疗或预防视网膜神经节细胞（RGC）死亡和/或青光眼的方法。 神经营养受体调节剂可以单独使用，和/或与一种或多种其它化合物，治疗或预防眼高血压，RGC死亡和/或青光眼的分子或药物结合使用。
-
6.发明授权公开(公告)号：US06610500B1
公开(公告)日：2003-08-26
申请号：US09091071
申请日：1998-06-08
申请人： H. Uri Saragovi , Lynne LeSauteur
发明人： H. Uri Saragovi , Lynne LeSauteur
IPC分类号： G01N3353
CPC分类号： A61K51/1045 , A61K38/00 , C07K14/71 , C07K16/2863 , C07K2317/77
摘要： The present invention relates to an agonistic anti-human TrkA mAb 5C3 which recognizes the NGF docking site. Such antibodies may be used for the treatment, diagnosis or prevention of neurological diseases, neuromas and neoplastic tumors which express TrkA receptors. Also these antibodies may be used to develop and screen for pharmaceutical agents which are agonistic or antagonistic to NGF binding to the TrkA receptors.
摘要翻译： 本发明涉及识别NGF对接位点的激动性抗人TrkA mAb 5C3。 这些抗体可用于治疗，诊断或预防表达TrkA受体的神经疾病，神经瘤和肿瘤性肿瘤。 也可以使用这些抗体来开发和筛选对TrkA受体结合的NGF具有激动作用或拮抗作用的药剂。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.015 秒)
